We’re pleased to announce we have successfully passed the TGO93 and TGO100 mandatory tests for our first commercial export crop. TGO93 and TGO100 specify the standard for quality requirements for medicinal cannabis products. Implemented by the Therapeutic Goods Administration (TGA), these standards ensure all medicinal cannabis manufacturers provide the highest quality and reliability in therapeutics goods on the market. We’re firmly on course for our first European export by the end of this year.
One of ANTG’s proprietary medicinal cannabis strains, EVE Cannabis Indica, has been listed on the Australian Register of Therapeutic Goods (ARTG). The ARTG is a reference of therapeutic goods that can lawfully be supplied in or exported from Australia.
In conjunction with the HMRI and lead biomedical scientist Dr Matt Dun, we’re investigating the anticancer properties of our plant varieties. Dr Matt Dun shares his initial thoughts on the joint research project.
We are focused on research and development, partnering with leading scientists and medical institutions to develop cannabinoid medicines that offer safe and effective therapeutic benefits.LEARN ABOUT ANTG HERE >